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Summary: The aim of this study was to analyze in detail the site of
metastasis of stage 4 Wilms tumor (WT) and its correlation with
outcome. The databases from 3 major European pediatric cancer
institutions were screened for children with WT between 1994 and
2011. Of 208 children identified, 31 (14.9%) had metastases at
diagnosis. The lung was affected in 29 children (93.5%) and the liver
in 6 children (19.4%). Twenty-seven children (87.1%) had metastases
isolated to 1 organ, with the lung being the most common site
(80.7%). Five-year overall survival was significantly better in those
children with distant disease in either lung or liver (95.8%) compared
with those affected in both lung and liver (57.1%, P=0.028).
Further, prognostic markers were the response of metastases
to preoperative chemotherapy (P=0.0138), high-risk histology
(P=0.024), and local stage (P=0.026). Five-year overall survival
was 82.1% and 5-year event-free survival was 67.9%. The overall
follow-up time was 74.1 and 87.2 (2 to 151) months among survivors,
and the treatment-related complication rate was 16.7%. In con-
clusion, in our series of stage 4 WT, prognosis was excellent if his-
tology was favorable, metastatic disease was isolated to either lungs
or liver, and if metastases responded to preoperative chemotherapy.
Key Words: metastases, pediatric cancer, risk stratification, sur-
vival, Wilms tumor
(J Pediatr Hematol Oncol 2013;35:518–524)
Wilms tumor (WT) is the most common renal malig-nancy in childhood and the second most frequent intra-
abdominal pediatric cancer after neuroblastoma.1 Many
recent advances in clinical care and the biology of this tumor
have pushed the overall survival (OS) to 90%. Naturally, for
children with distant metastases the OS is lower.1
Little is known on metastatic disease in stage 4 WT
and its implication on therapy and outcome.2,3 The lungs
have long been recognized as a common site of distant
tumor spread in stage 4 WT and several recent studies focus
on this entity.1,2 To our knowledge, no complete descrip-
tion of the metastatic profile of stage 4 WT at diagnosis
exists at present. Therefore, in this study we reviewed
children treated at 3 European pediatric cancer institutions
for WT regarding their metastatic profile at diagnosis and
its implication on long-term outcome.
METHODS AND PATIENTS
Patients
A retrospective analysis of the WT databases at the
following 3 institutions was carried out: Hannover Medical
School, Hannover (Germany); Dr. von Hauner Children’s
Hospital, Munich (Germany); and Virgen del Rocı́o Child-
ren’s Hospital, Seville (Spain). Inclusion criteria were meta-
static disease at diagnosis. Consequently, children with lower
stage tumors who relapsed with metastatic disease were
excluded. Additional exclusion criteria were other renal
tumor entities like clear cell sarcoma, rhabdoid tumor, or
renal cell carcinoma.
Treatment
Staging criteria for WT was based on an upfront che-
motherapy-based system developed by the International
Society of Pediatric Oncology (SIOP). Treatment was
according to SIOP protocols 93-01 and 2001 depending on
the time of diagnosis.2 These 2 treatment protocols were
similar with the exception of the use of cyclophosphamide in
SIOP 2001 instead of ifosfamide in SIOP 93-01. Radiologic
treatment response of metastases was classified as either
complete (disappearance), partial (regression of >50% of
size/number), poor response (or stable disease, <50%
regression of size/number), or progressive disease (increase in
size/number). Persistent metastatic lesions after preoperative
chemotherapy were considered for treatment with surgery,
radiation, or both. Those children who underwent adjuvant
radiation of pulmonary lesions, dose consisted of 15Gy to
both lungs. Surgery for metastatic disease was carried out
shortly after removal of the primary tumor. The choice of
surgical approach was due to the preference of the single
institutions. After achieving local control of primary and
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metastatic disease, adjuvant chemotherapy followed accord-
ing to histologic risk type.
Statistical Analysis
Survival and time-to-event analyses were performed
using the Kaplan-Meier method. The log rank (Mantel-
Cox) test was used to test differences between survival
curves. When comparing 2 survival curves, additional
hazard ratio with 95% confidence interval was calculated.
Aggregated data are represented using the usual descriptive
means. Additional statistical significance of differences
between groups was determined by the 2-tailed Student
t test for scale and the w2 test and Fisher exact test for
dichotomous and nominal variables. In the latter case, odds
ratios and 95% confidence intervals are given. All statistical
analysis was carried out with the GraphPad Prism Bio-
statistics Software (La Jolla, CA). All reported P-values are
2-sided. In all tests, differences were considered significant
at P<0.05.
RESULTS
For the time period from 1994 to 2011, a total of 208
children with WT were identified (Tables 1, 2). Of these,
31 children (14.9%) initially presented with metastatic dis-
ease (Table 2). Mean age at diagnosis was 64.8 months
(range, <1 to 203). Seventeen children (54.8%) were males,
and 14 (45.2%) were females (male to female ratio 1.2:1).
Twelve patients (38.7%) had unilateral WT on the left, 17
(54.8%) had unilateral WT on the right, and 2 (6.5%) had
bilateral disease (Table 1).
Metastatic Profile and Treatment Response
The lungs were the most common metastatic site in 29
children (93.5%), and 25 children (80.6%) had metastatic
disease isolated to the lungs (Table 1). Of the children with
pulmonary metastatic disease, the lung parenchyma was
infiltrated in 28 children (96.6%). One child (3.4%) had an
isolated malignant pleural effusion but otherwise clear
lungs on computed tomography (CT) scan.
TABLE 1. Patient Population and Pertinent Data
Primary Tumor Total (n [%])
Metastatic Profile and
Treatment Total (n [%]) Postoperative Events Total (n [%])
General Lungs or associated 29 (93.5) Postoperative chemotherapy 31 (100)
Age at diagnosis
(mo, range)
64.8 (< l-203) Isolated lungs 25 (80.6)
Male 17 (54.8) Lung parenchyma 28 (96.6) Radiation (total) 20 (64.5)
Female 14 (45.2) Pleura 2 (6.9) Chest 9 (45.0)
Male to female ratio 1.2:1 Pleural effusion 1 (3.4) Abdomen/tumor bed 15 (75.0)
Both 4 (20.0)
Localization Liver 6 (19.4) Recurrence 7 (22.6)
Left 12 (38.7) Isolated liver 2 (33.3) Local 1 (14.3)
Right 17 (54.8) Liver and lungs 3 (50.0) Distant 6 (85.7)














7 (70.0)* CTX (high-risk/
rescue protocol)
7 (22.6)
Liver resection 2 (20.0) Radiation 7 (22.6)
Local stage Metastasectomy 4 (12.9)w
I 11 (35.5) Radiation (to primary
metastases)
12 (38.7)z Autologeous stem
cell transplant
1 (3.2)
II 1 (3.2) Liver 0 (0)









Negative 13 (41.9) Complete necrosis 4 (12.9) Renal insufficiency
and scoliosis
1 (4.2)
Positive 10 (32.2) Regressive 7 (22.6) Cardiac arrhythmia 1 (4.2)
Not sampled/no
information
8 (25.8) Blastemal 12 (38.7) Cardiac insufficiency 1 (4.2)




Low risk 4 (12.9) Diffuse anaplasia 6 (19.4)
Intermediate risky 15 (48.4) Overall salvage rate 3 (42.9)
High risk 12 (38.7)
*One child had infectious pulmonary nodules.
wOne child had infectious pulmonary nodules.
zOne child did not have surgery or radiation.
yThree (9.7%) had blastemal types in 93-01.
CTX indicates chemotherapy; GI, gastrointestinal.
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Overall, 6 children (19.4%) presented with metastatic
disease in the liver. Three of these patients (50.0%) had
additional metastases in the lung, and 1 (16.7%) had
pulmonary lesions and bone metastases (ribs). The only
organ other than the lung to show isolated metastatic dis-
ease was the liver, and this was the case in 2 children (6.5%
of all patients).
After completion of preoperative chemotherapy and
before resection of the primary tumor, all children were
restaged with CT scan of the chest and abdomen. Overall,
23 children (74.2%) showed partial response and 2 children
(6.5%) showed complete response of metastases. Six chil-
dren (19.4%) showed no response. Of these, 3 children
(9.6%) showed stable metastatic disease, and 3 (9.6%) had
progressive metastatic disease.
The primary tumor of 28 children (90.3%) responded to
preoperative chemotherapy, 3 (9.7%) had no response
(Supplemental Table 1, http://links.lww.com/JPHO/A37).
Twenty-four children (77.4%) showed both a response of
primary tumor and metastatic disease. In 4 children (12.9%),
in which response of primary tumor was found, did not have
a response of metastatic disease. Two children (6.5%) showed
a response of metastatic disease, but not of primary tumor.
One child had no response to preoperative chemotherapy in
either. Therefore, response of metastatic disease to pre-
operative chemotherapy was more likely if the primary tumor
responded, but the difference was not significant (P=0.422;
Supplemental Table 1, http://links.lww.com/JPHO/A37).
There was no difference found in this respect for liver versus
lung metastasis (data not shown).
Treatment for Persistent Metastatic Disease
Unless complete response could be achieved with pre-
operative chemotherapy, metastatic disease was evaluated for
additional local treatment (Table 1). Overall, 8 children
(25.8%) received radiotherapy only, all for metastatic
pulmonary disease. Four children (50.0%) in this group died,
the other 4 (50.0%) were long-term survivors. Six children
FIGURE 1. Survival analysis Kaplan-Meier survival analysis is shown with hazard ratio (HR) and 95% confidence interval (in parenthesis).
P-value was calculated with the log rank (Mantel-Cox) test. A, the subgroups with high-risk versus low/intermediate-risk histology are
shown. The blastemal subgroup from SIOP 93-01 was assigned to the high-risk group (see text for details). Partial or complete response
to preoperative chemotherapy versus stable disease or disease progression (B). C, compares metastatic disease isolated to 1 organ (lung
or liver) versus 2 organs (lung and liver). D, surgery either alone or together with radiation is shown versus radiation alone.
TABLE 2. Five-year OS and 5-year EFS
Survival Total
Total number of WT 208
Stage 4 disease 31
% Stage 4 from all 14.9
5-y OS (%) 82.1
5-y EFS 67.9
Deaths 7 (22.5%)*
Five-year OS and 5-year EFS are shown as percent value for all children.
*Of note, 2 children died of disease progression shortly after completing
the 5-year follow-up (61 and 68mo) and are listed separately.
EFS indicates event-free survival; OS, overall survival; WT, Wilms
tumor.
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(19.4%) underwent surgical resection of metastatic disease in
either lung (N=4, 66.7%) or liver (N=2, 33.3%) without
additional radiation. All 6 children survived long term. Four
(12.9%) underwent both surgical resection and radiation of
primary metastatic disease, and 1 child died, the other 3
survived long term. Therefore, even though not significant, a
clear trend was observed toward survival for those children
who received either surgery or surgery and radiation versus
radiation alone (P=0.097, Fig. 1D).
Of the 10 children undergoing surgical resection, 7
children (70.0%) received open metastasectomies for lung
metastasis (either sternotomy or thoracotomy), and R0
resection was achieved in 4 children (57.1%). All 4 showed
regressed, nonviable tumor. One child had R2 resection
(miliary metastatic disease of lung), histology showed viable
tumor, and the child did not survive. Of the remaining 2
children, 1 child had R2 resection, the other, even though
correctly diagnosed as stage 4 and who showed partial
response to some but not all pulmonary nodules, was found
to have inflammatory (septic) lung granulomas in the
resected specimen. In the child with R2 resection, apart
from atypical lung resection of obvious metastatic disease, a
suspicious pleural lesion was identified but not resected.
This lesion completely regressed with postoperative che-
motherapy. Later, the child relapsed with pulmonary dis-
ease independent from the pleural lesion.
One child (10.0%) underwent thoracoscopic meta-
stasectomy and histology showed viable tumor, but resec-
tion was R0. He is currently alive at 18 months.
The 2 children (22.2%) who had isolated liver meta-
stasis (and clear lungs) underwent R0 liver resection, his-
tologically both showed regressed, nonviable tumor. None
of 2 relapsed. The other 4 children with metastatic liver
disease (in addition to lung disease) received radiation to
the lungs but no additional treatment of the liver meta-
stasis, and 3 of these 4 patients died.
Local Stage
Following SIOP guidelines, children were restaged
after resection of the primary tumor. Eleven children
(35.5%) had local stage I disease, 1 child (3.2%) had local
stage II disease. Nineteen children (61.3%) had local stage
III disease and were treated with additional adjuvant
radiation to the tumor bed (Table 1).
Local stage was neither associated with whether 1 (lung
or liver) or 2 organs (lung and liver) were affected (Supple-
mental Table 2, http://links.lww.com/JPHO/A38; P=0.139),
nor with the response of primary or metastatic disease to
preoperative chemotherapy (P=0.544 and 0.630, respec-
tively). Correspondingly, none was associated with histologic
risk type (P=0.484) or recurrence (P=1.000). Local stage
was, however, associated with survival (P=0.026).
Histology and Risk Stratification
The overall histologic distribution in the primary
tumors is shown in Table 1. Four children (12.9%) had
complete necrosis and 7 (22.6%) regressive changes. Twelve
children (38.7%) had a blastemal subtype, 3 children
(9.7%) had an epithelial type, and 5 children (16.1%) were
mixed. Six children had additional diffuse anaplasia (5
diffuse, 1 diffuse and focal).
Histologically, 4 children (12.9%) were considered low
risk, 15 (48.4%) were of an intermediate type. Twelve chil-
dren (38.7%) were high risk (Table 1). Importantly, histologic
risk stratification of pretreatedWTwas different for SIOP 93-
01 and SIOP 2001. In SIOP 93-01, blastemal predominant
subtype was regarded as intermediate-risk histology. In SIOP
2001, it was considered high risk and was treated accordingly
with intensified chemotherapy. Therefore, we compared the
outcomes of the blastemal subtype between the 2 protocols
and found a possible trend regarding survival, but no sig-
nificant difference (P=0.206; Supplemental Table 4, http://
links.lww.com/JPHO/A40 top row). In accordance with
similar studies,2 for a common analysis, blastemal subgroups
from both SIOP 93-01 and SIOP 2001 were assigned to the
high-risk group. High-risk histology of primary tumor was a
strong predictor for survival (high risk vs. low/intermediate
risk; Table 3; Fig. 1A). Comparing the blastemal predom-
inant subtype with the diffuse anaplasia subtype within the
high-risk group of both SIOP 93-01 and SIOP 2001 or SIOP
2001 alone, we found a trend regarding survival, but no
significant difference (Supplemental Table 4, http://links.
lww.com/JPHO/A40 middle and bottom row).
TABLE 3. Survivors Versus Nonsurvivors
Survivors NonSurvivors P Odds Ratio 95% CI
No. Children 24 7
Age at diagnosis 64.75 (0-203) 64.86 (1-160) 0.9958 NA NA
Sex (female) 12 (50%) 2 (28.6%) 0.4117 NA NA
Metastasis isolated to 1 organ (lung or liver) 23 (95.8%) 4 (57.1%) 0.0278* 17.25 1.415-210.2
Metastasis in 2 or more organ systems 1 (4.2%) 3 (42.9%)
Partial or complete response of primary disease 22 (91.7%) 6 (85.7%) 0.5497 1.833 0.141-23.84
No response of disease progression 2 (8.3%) 1 (14.3%)
Partial or complete response of metastatic disease 22 (91.6%) 3 (42.9%) 0.0138* 14.67 1.827-117.7
No response of disease progression 2 (8.3%) 4 (57.1%)
Recurrence (after established remission)z 3 (12.5%) 4 (100.0%) 0.0017w 0.01809 0.0007-0.4151
No recurrence (after established remission)z 21 (87.5%) 0 (0.0%)
High-risk histology 4 (16.7%) 5 (71.4%) 0.0118* 0.080 0.0112-0.5682
Low-risk/intermediate-risk histology 20 (83.3%) 2 (28.6%)
Statistical analysis calculated with Fisher exact test with P-value, odds ratio, and 95% CI are shown for survivors versus nonsurvivors. All survivors lived at
least 5 years except in 2 cases, in which survival was at least 18 months and follow-up is currently ongoing.
*Statistical significance with a P-value <0.05.
w Significance with a P-value <0.01.
zFor analysis of recurrence, distribution was calculated without 3 children who died of disease progression without ever achieving complete remission.
CI indicates confidence interval; NA, not applicable.
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The histologic evaluation of the tissue obtained from the
10 children who received surgical resection of metastatic
disease was compared with the histology of the primary
tumor (Supplemental Table 3, http://links.lww.com/JPHO/
A39). In 5 children (50.0%), tissue was found to be nonviable
tumor. In 2 children (20.0%), histology was unavailable. In 1
case, no tumor tissue was found (erroneous diagnosis, see
below). Two children showed viable tumor tissue, and his-
tology corresponded to that of the primary tumor in both
cases. One had a mixed, the other a blastemal subtype. The
latter was the only one to die from this group (Supplemental
Table 3, http://links.lww.com/JPHO/A39).
Recurrence
Seven children (22.6%) achieved complete primary
remission and then relapsed at a later time (Table 1).
Relapse was early (<12mo after achieving complete
remission) in 6 children (85.7%) and late (>12mo) in
1 child (14.3%). However, the latter (late relapse) relapsed
at 13 months of age. One child (12.5%) had local relapse
and was treated with local reexcision and local radiation.
He was well without disease 10 years after recurrence. Six
children (85.7%) had distant recurrence, of which 4
(66.7%) died. Therefore, the overall salvage rate for relapse
disease in our cohort was 42.9% (Table 1).
From the 4 children who relapsed and died, the first
had blastemal histology, relapsed at 13 months, received
radiation, surgical resection, chemotherapy, and autolo-
gous stem cell transplantation. The next had blastemal
histology, relapsed early, and received only chemotherapy
following to the parents’ wishes. The third had regressive
histology, relapsed early, had radiation and chemotherapy
but no surgery, and died rapidly. The fourth again had
blastemal histology, relapsed early, and received radiation,
multiple resections of metastatic pulmonary disease, and
intensified chemotherapy, all without success. Of the 2
children who relapsed distantly and survived, both relapsed
early with lung metastasis. One had a blastemal subtype
histology and received chemotherapy and radiation and
was in remission and well 11 years after relapse. The other
had mixed histology with diffuse anaplasia and received
surgery, radiation, and chemotherapy and was in remission
7 years after relapse.
Survival Analysis and Prognostic Factors
For all children, 5-year event-free survival was 67.9%
and 5-year OS was 82.1% (Table 2; Fig. 2). Seven children
(22.5%) died. Of these, 4 children (57.1%) died after
relapsing distantly and 3 (42.9%) died from disease pro-
gression before reaching full remission in 2 cases and
intraoperatively from severe hemorrhage in 1 case. With
regard to OS, several prognostic factors were appreciated.
Survival was significantly better in children with metastases
to either lung or liver compared with involvement of both
lung and liver (Table 3; Fig. 1C). Therapeutic response of
metastases to preoperative chemotherapy, regardless of its
location, was associated with survival (Table 3; Fig. 1B).
Long-term Follow-up
The overall follow-up time for all children was 74.1 (2 to
151) and for the survivors 87.2 (2 to 151) months. Survivors
who received radiation of the lung as part of their therapy (7
children) were followed with chest x-ray and/or pulmonary
function test in all cases, and none showed sign of fibrosis
(0%). However, 1 child (4.2%) developed thoracolumbar
scoliosis (this child also had thoracotomy for meta-
stasectomy). Seventeen of the 24 survivors (70.8%) under-
went either electrocardiography and/or cardiac sonogram
during follow-up, which was not performed routinely in all
centers after chemotherapy. One child (4.2%) was found to
have cardiac arrhythmia and another congestive heart failure.
Creatinine levels were analyzed after completion of
treatment and were within normal limits in all but 1 case
(4.2%). This child developed chronic renal insufficiency
independent from the type of surgery (partial nephrectomy
for bilateral disease vs. unilateral tumornephrectomy).
Tubulopathy was confirmed by biopsy. One child had
chronic loose stools, which affected social life (Table 1).
Overall, among the long-term survivors 4 children
(16.7%) developed at least one of the aforementioned
treatment-related complications.
DISCUSSION
Warmann et al2 recently reported on 210 patients with
WT and primary lung metastases. Five-year OS was 83.3%
and 5-year event-free survival 72.3%, respectively, for all
children. This is similar to what we report for our study.
Corresponding to our results, which showed strong corre-
lation between histologic risk type and survival, in their
study survival was significantly worse in children with high-
risk primary histology. In addition, they were able to show
that within the high-risk group, the blastemal subtype was
associated with significantly better outcome than the diffuse
anaplasia subgroup. In our study, we observed a similar
trend; however, perhaps because of a lower number of
cases, we found no significant difference. In the study of
Warmann et al,2 a poor prognostic marker was no response
to chemotherapy both for the primary tumor and meta-
static disease. In the patient cohort presented here, we
found increased survival only in those children who showed
response to metastatic disease but not to the primary tumor
itself. Likewise, these findings could potentially been biased
by our low case number.
Breslow et al3 in the past have given a detailed analysis
on the metastatic pattern of children with stage IV WT. In
their comprehensive study, no difference was identified in
survival according to metastatic site (liver and/or lung vs.
lung only). However, these data were extracted from the
FIGURE 2. Overall survival and event-free survival for the total
population.
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National Wilms Tumor Study (NWTS) during 1969 to 1983
and are therefore difficult to compare with our data
extracted from the more recent SIOP protocols.
When interpreting survival analysis with regard to
histologic risk stratification, several vital aspects need to be
pointed out. Importantly, blastemal subtype histology was
handled differently in SIOP 93-01 and SIOP 2001.
Although in SIOP 2001 it was considered high risk and
received intensified chemotherapy, in SIOP 93-01 it was
classified as intermediate risk and treated accordingly.
Upon analysis of the blastemal subtype between the 2
protocols, we found no difference. For common analysis in
this study, blastemal subtype in SIOP 93-01 was assigned to
the high-risk group. This is in accordance with others.2
In our study, complete response (disappearance) of
metastatic disease was seen only in 2 patients. This is in
sharp contrast to what has been reported by others.2,4 We
explain this with the significantly higher usage of CT scan
for restaging in our study. There is an ongoing debate
about which diagnostic modality is appropriate for staging
distant disease in WT.5 In this respect, it is important to
note that in children with WT not all lesions detected on CT
scan are necessarily metastatic in origin.6 In our study, 1
child who underwent pulmonary resection for suspected
metastatic disease and another for recurrent pulmonary
disease, histologic diagnosis was erroneous (nonmalignant).
Surgical treatment of pulmonary metastasis, whether
alone or together with radiation, resulted in better outcome
compared with radiation in our study. These findings go
along with accumulating evidence identifying surgery as a
safe and valuable tool for local control of metastatic disease.7
One advantage of surgical resection of metastasis is the gain
of additional tissue analysis, possibly altering therapeutic
behavior. In our study, for the patients who underwent sur-
gery for primary metastatic disease, tissue analysis mostly
showed nonviable tumor corresponding with the histology of
the primary tumor. Unfortunately, in which clinical situation
surgery is indicated exactly and when it should be favored
over radiation we cannot extract from our data.
In a SIOP series of children with WT and primary
hepatic metastases, Szavay et al8 suggested that initial
surgical resection improved survival. In our study, 2 chil-
dren had isolated liver metastases, both underwent ana-
tomic resection at the time of operation of the primary
tumor, and both survived long term. Three of the 4 children
with both liver and lung metastases died. Therefore, in our
study the presence of liver metastases seemed to be an
adverse finding only in combination with additional
pulmonary lesions. None of these 4 children underwent
resection of their hepatic lesions. Of the 3 children who
died, 2 showed progression of liver and pulmonary meta-
stasis and 1 showed progression of pulmonary metastasis
only. With respect to their primary histology, 1 had diffuse
anaplasia and 2 had blastemal histology, as did the child
who survived. It is tempting to speculate that the children
who died in this group might have benefited from meta-
static resection either at tumor excision or at a later time.
Whether this is truly the case, however, must be shown in
larger series focusing on this important detail.
Shamberger et al9 showed in 2482 patients from NWTS-
4 that advanced local tumor stages (especially local stage III)
were associated with adverse outcome. However, these
patients were mainly nonmetastatic patients. In our patient
sample, there was a significant difference regarding survival
for local stage I and II versus local stage III disease. We saw
no association between local stage and histology or the
presence of metastatic disease in 1 versus 2 organs.
Relapse after achieving complete remission is a sig-
nificant problem in WT with poor outcome.10 It is reported
to occur in approximately 10% to 20% of cases and fun-
damentally depends on tumor stage and biology at initial
diagnosis.10–13 The recurrence rate in our patient collective
was 22.6%. Advances in rescue protocols mainly consisting
of intensified chemotherapy regimens have lead to salvage
rates of 50% to 70% overall, depending on the tumor
biology, disease stage, and other characteristics such as the
length of remission.10,13,14 The salvage rate in our study for
stage 4 disease independent of tumor histology was 42.9%
and therefore somewhat lower.
In our cohort, overall treatment-related long-term
complications among the survivors at a mean of >7 years
was 16.7%. This number is difficult to compare with others
because of the selected patient cohort in our study. It is a
key future objective to further reduce treatment intensities
without compromising the patient’s prognosis.10,15–19 None
of the children who received radiation to the lung devel-
oped pulmonary fibrosis. One child in this group, however,
developed thoracolumbar scoliosis, potentially due to a
combination of thoracotomy and radiation. Whether this
complication could have been avoided with a thoracoscopic
approach for metastasectomy without compromising
prognosis is impossible to extract from our data. The pre-
cise role for minimal-invasive surgery for selected cases in
WT remains to be clarified. Selection criteria for minimal-
invasive surgery, potentially including the histology of the
tumor,2 should be adapted into present guidelines and
protocols, and evaluation must include both the surgical
and oncological outcome.
The same child who had developed scoliosis also
developed renal insufficiency with confirmed tubulopathy.
Important, this child was initially treated with SIOP 93/01
and therefore received ifosfamide; also, the child relapsed
and was treated with additional chemotherapy. With ade-
quate medical therapy, the child currently has a borderline
normal creatinine level at 12-year follow-up.
One child developed toxic cardiopathy (after SIOP 93/
01) and another cardiac arrhythmia (after SIOP 2001).
None of the 2 underwent radiation therapy to the chest.
One child developed chronic loose stools, possibly related
to partial colectomy required during tumornephrectomy.
Taken together, in our cohort of stage 4 WT, with
current treatment strategies the overall prognosis is
acceptable, and long-term follow-up showed little toxicity
from the invasive therapy. However, many questions
remain unanswered including the optimal diagnostic
workup, the treatment of distant disease, the appropriate
surgical approach, and the role of biological markers as
additional tools for risk stratification.
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